Fate Therapeutics, Inc. FATE 深 沪
已收盘 05-15 16:00:00 美东时间
1.755
-0.145
-7.63%
华盛通- 最 高1.91
- 今 开1.86
- 成交量 206.77万股
- 最 低 1.71
- 昨 收 1.90
- 总市值 2.04亿
- 52周最高 2.465
- 市盈率 静 --
- 换手率 1.78%
- 52周最低 0.91
- 委 比 -60.62%
- 总股本 1.16亿
- 历史最高 121.16
- 量 比 0.59
- 振 幅 10.53%
- 历史最低 0.6611
- 每 手 1
- 风险率 0.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 18.75 percent increase over losses of $(0.32) per share from
05-13 20:33
Fate Therapeutics To Present Data For Its Off-The-Shelf CAR T-Cell Programs At American Society Of Gene And Cell Therapy Annual Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to
05-11 20:33
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
05-07 01:35
美股牛股 | AI“带飞”建筑巨头！STRL绩后股价狂飙逾50%，光互连概念POET单日反弹逾29%
AI“带飞”建筑巨头！STRL绩后股价狂飙逾50%，Q1营收猛增91%；光互连概念POET单日反弹逾29%>>
05-06 19:14
美股牛股 | 多重利好！Circle大涨近20%，CLARITY法案取得关键进展并获但斌买入；GBTG飙升超57%
多重利好！Circle大涨近20%，CLARITY法案取得关键进展并获但斌买入；GBTG飙升超57%，获Long Lake以63亿美元收购>>
05-05 18:24
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
Fate Therapeutics To Present Clinical Data From Its FT819 Candidate At Congress Of Clinical Rheumatology In Florida
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with
04-30 21:02
Fate Therapeutics Says Preclinical Data From Next-Gen, Off-The-Shelf CAR T-Cell Product Candidate, FT839, To Be Featured At 2026 AACR Annual Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with
04-16 21:09
Scalable Biotech Manufacturing Unlocks a $14B Market
Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — The global cell therapy manufacturing market is hitting a pivotal inflecti...
03-27 21:15
Earnings Summary: Fate Therapeutics Q4
Fate Therapeutics (NASDAQ:FATE) just disclosed its Q4 earnings on Thursday, Feb...
02-26 22:06
